NCT01184833View on ClinicalTrials.gov

Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis

CompletedOBSERVATIONAL

Enrollment

852

Participants

Timeline

Start Date

September 30, 2008

Study Completion Date

August 31, 2011

Conditions

Multiple Sclerosis

Interventions

DRUG

Interferon beta-1b (Betaseron, BAY86-5046)

Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under the routine practice setting.

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY